The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives.
data integration
multi-omics
oncology
precision medicine
rare ovarian cancers
systems biology
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
15 Oct 2021
15 Oct 2021
Historique:
received:
20
09
2021
revised:
05
10
2021
accepted:
12
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Rare ovarian cancers are ovarian cancers with an annual incidence of less than 6 cases per 100,000 women. They generally have a poor prognosis due to being delayed diagnosis and treatment. Exploration of molecular mechanisms in these cancers has been challenging due to their rarity and research efforts being fragmented across the world. Omics approaches can provide detailed molecular snapshots of the underlying mechanisms of these cancers. Omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, can identify potential candidate biomarkers for diagnosis, prognosis, and screening of rare gynecological cancers and can aid in identifying therapeutic targets. The integration of multiple omics techniques using approaches such as proteogenomics can provide a detailed understanding of the molecular mechanisms of carcinogenesis and cancer progression. Further, omics approaches can provide clues towards developing immunotherapies, cancer recurrence, and drug resistance in tumors; and form a platform for personalized medicine. The current review focuses on the application of omics approaches and integrative biology to gain a better understanding of rare ovarian cancers.
Identifiants
pubmed: 34680597
pii: biomedicines9101481
doi: 10.3390/biomedicines9101481
pmc: PMC8533212
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Comput Struct Biotechnol J. 2021 Jan 22;19:949-960
pubmed: 33613862
Hum Pathol. 2011 Jul;42(7):918-31
pubmed: 21683865
Eur J Cancer. 1996 Apr;32A(4):593-7
pubmed: 8695258
Nat Cell Biol. 2017 Aug;19(8):962-973
pubmed: 28737768
BioData Min. 2020 Aug 24;13:10
pubmed: 32863885
Science. 2010 Oct 8;330(6001):228-31
pubmed: 20826764
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Br J Cancer. 2017 Aug 22;117(5):717-724
pubmed: 28728166
Oncogene. 2013 May 30;32(22):2739-46
pubmed: 22797072
AJR Am J Roentgenol. 2006 Jul;187(1):99-104
pubmed: 16794162
Clin Cancer Res. 2019 May 15;25(10):3006-3015
pubmed: 30979733
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Front Mol Biosci. 2018 Aug 27;5:76
pubmed: 30211169
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Genome Med. 2015 Aug 07;7(1):87
pubmed: 26257827
BMC Cancer. 2014 Feb 22;14:120
pubmed: 24559118
Proteomics Clin Appl. 2013 Jun;7(5-6):355-66
pubmed: 23161554
Proteomics. 2010 Nov;10(21):3800-10
pubmed: 20960451
Eur J Cancer. 2011 Jun;47(9):1420-31
pubmed: 21334202
J Pathol. 2021 Jan;253(1):41-54
pubmed: 32901952
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
Semin Immunol. 2013 Oct 31;25(3):201-8
pubmed: 23238271
Endocr Rev. 2012 Feb;33(1):109-44
pubmed: 22240241
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
Gynecol Oncol. 2016 Jun;141(3):602-607
pubmed: 26873864
Mod Pathol. 2013 Jun;26(6):860-7
pubmed: 23348906
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Proteomics. 2006 Nov;6(21):5880-90
pubmed: 17022098
Gynecol Oncol. 2010 Oct;119(1):53-9
pubmed: 20580063
Sci Rep. 2020 Sep 10;10(1):14877
pubmed: 32913236
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Cancer Res. 2009 Sep 1;15(17):5404-13
pubmed: 19690197
Cancer Treat Rev. 2009 Nov;35(7):608-15
pubmed: 19665848
Br J Cancer. 2016 Jun 14;114(12):1412-20
pubmed: 27253175
Insights Imaging. 2021 May 11;12(1):60
pubmed: 33974157
Front Oncol. 2020 Dec 22;10:598579
pubmed: 33415077
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487856
Gynecol Oncol. 2017 Dec;147(3):695-704
pubmed: 29037806
Elife. 2017 Oct 31;6:
pubmed: 29087294
Curr Oncol. 2007 Oct;14(5):195-208
pubmed: 17938703
Oncogene. 2018 Aug;37(33):4611-4625
pubmed: 29760405
Cell. 2016 Jul 28;166(3):755-765
pubmed: 27372738
Genes Chromosomes Cancer. 2018 Feb;57(2):51-60
pubmed: 29044863
Oncotarget. 2016 Mar 22;7(12):14207-19
pubmed: 26893359
Expert Rev Proteomics. 2016;13(3):297-308
pubmed: 26697917
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9
pubmed: 22436749
Histopathology. 2016 Jan;68(2):279-85
pubmed: 26033501
Lancet Oncol. 2010 Jul;11(7):685-93
pubmed: 20362508
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
Int J Oncol. 2016 Oct;49(4):1651-65
pubmed: 27511453
Acta Oncol. 2012 Apr;51(4):473-9
pubmed: 22283470
Comput Struct Biotechnol J. 2021 Jun 22;19:3735-3746
pubmed: 34285775
Front Oncol. 2020 Jun 30;10:1030
pubmed: 32695678
PLoS Comput Biol. 2021 Aug 12;17(8):e1009224
pubmed: 34383739
Mol Cancer Ther. 2016 Jul;15(7):1472-84
pubmed: 27364904
Clin Cancer Res. 2002 Jul;8(7):2448-54
pubmed: 12114452
Cancer Biol Ther. 2015;16(2):336-45
pubmed: 25756516
Cancer Sci. 2012 Apr;103(4):747-55
pubmed: 22321069
PLoS One. 2018 Nov 1;13(11):e0206785
pubmed: 30383866
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
J Proteome Res. 2013 Oct 4;12(10):4340-50
pubmed: 23805888
Oncotarget. 2017 Jul 18;8(29):46891-46899
pubmed: 28423358
Nat Med. 2015 Mar;21(3):231-8
pubmed: 25686104
Nat Commun. 2019 Apr 8;10(1):1600
pubmed: 30962452
Bioinform Biol Insights. 2020 Jan 31;14:1177932219899051
pubmed: 32076369
Methods Mol Biol. 2019;1871:197-224
pubmed: 30276742
Int J Oncol. 2017 Apr;50(4):1431-1438
pubmed: 28259988
J Pathol. 2013 Jan;229(1):111-20
pubmed: 22899400
J Proteome Res. 2014 Mar 7;13(3):1624-35
pubmed: 24498956
Hum Pathol. 2015 Oct;46(10):1427-36
pubmed: 26243671
Cancer Res. 2020 Apr 1;80(7):1475-1485
pubmed: 32019869
Curr Opin Biotechnol. 2017 Feb;43:34-40
pubmed: 27580257
Plant Mol Biol. 2002 Jan;48(1-2):155-71
pubmed: 11860207
Exp Mol Med. 2020 Sep;52(9):1452-1465
pubmed: 32929226
BMC Cancer. 2015 May 19;15:415
pubmed: 25986173
Cell Death Dis. 2018 Oct 22;9(11):1076
pubmed: 30348959
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
J Proteome Res. 2007 Jul;6(7):2631-9
pubmed: 17518487
Cancers (Basel). 2021 Jan 27;13(3):
pubmed: 33514073
J Proteome Res. 2015 Jun 5;14(6):2446-56
pubmed: 25871347
J Proteomics. 2015 Sep 08;127(Pt A):80-8
pubmed: 25952687
Hum Mol Genet. 2015 Dec 1;24(23):6687-98
pubmed: 26362254
Nat Commun. 2019 Sep 2;10(1):3935
pubmed: 31477716
Nature. 2000 Jun 15;405(6788):837-46
pubmed: 10866210
Gynecol Oncol. 2016 Jan;140(1):138-44
pubmed: 26521694
Cancer Control. 2020 Jan-Dec;27(1):1073274820976671
pubmed: 33297760
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Biomed Res Int. 2018 Oct 3;2018:9836256
pubmed: 30402498
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
PLoS One. 2016 Oct 31;11(10):e0165609
pubmed: 27798689
Eur J Surg Oncol. 2019 Jan;45(1):67-74
pubmed: 29108961
EPMA J. 2018 Feb 21;9(1):77-102
pubmed: 29515689
Oncotarget. 2015 Nov 10;6(35):37663-77
pubmed: 26506417
Gynecol Oncol. 2016 Nov;143(2):367-370
pubmed: 27531571
Clin Cancer Res. 2005 Sep 15;11(18):6422-30
pubmed: 16166416
J Proteome Res. 2014 Nov 7;13(11):4959-69
pubmed: 25083560
Metabolomics. 2018 Nov 24;14(12):154
pubmed: 30830441
Clin Chem. 2001 Oct;47(10):1901-11
pubmed: 11568117